Notably, BTNL2 mRNA induction was much greater than PD-L1 induction in LLC tumours, which may explain at least in part the significant impact of anti-BTNL2 mAb treatment on LLC tumour growth relative to anti-PD-1 mAb treatment (Supplementary Fig. 2c). The gene discussed is BTNL2; the disease is neoplasm.